What Is Testosterone Enanthate?

Uses, dosage, side effects, and contraindications

Table of Contents
View All
Table of Contents

Testosterone enanthate, also known as testosterone heptanoate, is an anabolic and androgenic steroid (AAS) drug used to treat low testosterone levels. Anabolic drugs work by building muscles, while androgenic refers to the enhancement of sex characteristics typically associated with males.

Used in medical procedures since the 1950s, testosterone enanthate is marketed under numerous brand names, including Androfil, Andropository, Cernos, Delatestryl, Depandro, Durathate, Everone, Sustrone, Testanon, Testanova, Testrin, Testostroval, Testoviron, and Testro.

As a schedule III drug, testosterone enanthate is available by prescription only.

A close-up of a syringe


Testosterone enanthate is classified as an AAS because it is both a synthetic derivative of testosterone and a testosterone pro-drug, meaning that it stimulates the body to produce testosterone on its own. With that being said, it has stronger androgenic effects and only moderate anabolic effects.

The drug is suitable for testosterone replacement therapy (TRT) in cisgender men with hypogonadism (the diminished production of testosterone in the testes). Causes of hypogonadism include testicular injury, infection, and cancer.

Radiation and chemotherapy can also cause hypogonadism, as can congenital disorders such as Klinefelter syndrome and diseases of the hypothalamus and pituitary gland (both of which stimulate testosterone production).

Testosterone levels in cis men can often decline steeply after the age of 50, leading to a condition known as andropause in which vigor and sexual desire are affected. Older cis men with symptoms of andropause (including fatigue and low libido) will often benefit from TRT.

Testosterone enanthate can also be used for hormone therapy in transgender masculine people, to treat delayed puberty in cisgender boys, and to manage inoperable metastatic breast cancer (breast cancer that has spread) in those who are postmenopausal.

The drug is also sometimes used, controversially, as an anti-aging therapy in older cis men.


Testosterone enanthate is a clear or yellowish viscous fluid supplied in a 5-milliliter (mL) multi-use glass vial. It is injected intramuscularly into the buttocks every one to four weeks. To avoid the fluctuating hormone levels (and the associated mood swings), lower dosages are often prescribed over shorter intervals.

The active drug, which is suspended in sesame oil, has a sustained release period of two to three weeks. The dosage may vary by individual but is typically prescribed as follows:

  • Male hypogonadism: 50 to 400 milligrams (mg) every two to four weeks
  • Delayed male puberty: 5 to 200 mg every two to four weeks for four to six months
  • Metastatic breast cancer: 200 to 400 mg every two to four weeks
  • Transgender hormone therapy: 50 to 200 mg per week or 100 to 200 mg every two weeks

While testosterone enanthate is sometimes used interchangeably with testosterone cypionate (depo testosterone), the latter is not approved to treat delayed male puberty, to manage metastatic breast cancer, or for transgender hormone therapy.

Side Effects

As a substance designed to alter hormone levels, testosterone enanthate has both its clear benefits and risks. The side effects can range from mild to intolerable.

The most serious side effects are associated with testosterone abuse, an increasing problem in the United States which led the U.S. Food and Drug Administration (FDA) to change the product warning label in 2016.

Common Side Effects

According to the FDA, the most common side effects associated with testosterone enanthate use include:

  • Injection site pain and swelling
  • Headaches
  • Dizziness
  • Mood changes, including aggression
  • Depression or anxiety
  • Increased or decreased libido
  • Generalized tingling sensations
  • Oily skin and acne
  • Thinning hair
  • Weight gain

The severity of side effects is typically dose-dependent and may be alleviated by reducing the current dosage.

Adverse Reactions

Less common but potentially more serious are side effects associated with the long-term use or overuse of testosterone enanthate. Some are related to the androgenic effects of the drug; others can affect the heart and liver by elevating the cholesterol and liver enzyme levels.

Call a doctor if you develop any of the following:

  • Male-pattern hair loss
  • Male-pattern hair growth in those assigned female at birth (hirsutism)
  • Male breast enlargement (gynecomastia)
  • Deepening voice in cisgender women
  • Menstrual irregularities, (including amenorrhea)
  • Clitoral enlargement
  • Prolonged painful penile erections (priapism)
  • Difficulty urinating or frequent urination at night in those with a penis
  • Severe psychiatric symptoms, including major depression, paranoia, or psychosis

Some androgenic effects seen in those assigned female at birth, such as clitoral enlargement and the deepening of the voice, are irreversible once they develop. A low sperm (oligospermia) can impair fertility in cisgender men.

The excessive use of testosterone can also increase the risk of a heart attack, stroke, congestive heart failure, and deep vein thrombosis (DVT), especially in cisgender men.

Severe liver injury can also occur, characterized by symptoms of fatigue, abdominal pain, nausea, vomiting, dark urine, and the yellowing of the eyes and skin (jaundice).

Call 911 or seek emergency care if you have signs of a cardiovascular event, including shortness of breath, rapid breathing, profuse sweating, trouble speaking, severe headaches, weakness on one the side of the body, or severe shooting pains in the left arm, jaw, or chest.


There are certain drugs that interact with testosterone enanthate. Some may need to be substituted or dose-adjusted. Alternately, other forms of androgenic therapy can be explored, including lower dose testosterone patches.

Among the possible drug-drug interactions:

  • Anticoagulants ("blood thinners") like warfarin often have increased drug activity when used with testosterone, increasing the risk of bleeding.
  • Diabetes drug doses may need to be adjusted as testosterone may decrease both blood sugar and insulin requirements.
  • Corticosteroids and testosterone need to be used with caution in people with heart, kidney, or liver disease as the combined use may promote fluid retention (edema) and increase the risk of congestive heart failure.


There are conditions in which testosterone enanthate should not be used under any circumstance. This includes the use of testosterone in untreated prostate cancer or breast cancer and in pregnancy. The drug should also be avoided if you are allergic to sesame oil or any components of the drug.

Prostate Cancer Risk

The prostate gland is an organ in those assigned male at birth whose role it is to secrete prostate fluid, one of the components of semen. The gland is dependent on androgens to function and will decrease the production of prostate fluid if the androgen level is low.

In tandem with this decrease is an increase in the risk of prostate gland enlargement, a condition referred to as benign prostatic hyperplasia (BPH). The enlargement not only obstructs the flow of urine; it can also lead to bladder stones and reduced kidney function.

Testosterone replacement therapy is known to improve urinary symptoms in those assigned male at birth with BPH. Moreover, it appears to do so without increasing the risk of prostate cancer.

The same may not be true for those assigned male at birth diagnosed with a prostate malignancy. While the association between testosterone use and prostate cancer remains highly controversial, there have been reports, mostly anecdotal, that testosterone use in older men with untreated prostate cancer led to metastasis.

With that being said, a 2011 study from Harvard Medical School concluded that there was no link between disease progression and testosterone use in 13 cisgender men with untreated prostate cancer who were on treatment for an average of 2.5 years. Other studies have reached a similar conclusion.

Despite the continued controversy, the FDA strongly advises against the use of testosterone in cisgender men with untreated prostate cancer.

Even for cis men without cancer, any elevation in the prostate-specific antigen (PSA) test within the first three to six months of starting testosterone would warrant the cessation of treatment until a complete cancer investigation can be completed.

Male Breast Cancer Risk

The evidence supporting the avoidance of testosterone in cis men with untreated breast cancer is equally uncertain, although a retrospective study conducted in 2006 suggested an 11 percent increase in male breast cancer risk over a 10-year period. The mechanism for this association is poorly understood, and many don't believe that it actually exists.

For cisgender men with untreated breast cancer, the FDA remains adamant that the use of testosterone poses a potential threat and should be avoided without exception.

Risk in Pregnancy

The use of testosterone enanthate in those who are pregnant is contraindicated. When administered during pregnancy, testosterone can cause the virilization of a female fetus, a condition known as gestational hyperandrogenism in which physical characteristics typically associated with those assigned male at birth are present in a fetus assigned female.

Some of the symptoms of virilization may be seen at birth, while others may only become apparent during puberty or later in life. They include:

  • An enlarged clitoris and external genitals
  • Ovarian cysts, even in childhood
  • Excessive body or facial hair
  • Larger bone structure
  • Smaller breasts
  • Hair thinning characteristic of male pattern baldness
  • Deeper voice

The risk of virilism is higher in birthers who themselves are experiencing virilism as a result of testosterone use.

Testosterone therapy must be stopped if a pregnancy is suspected, especially during the first trimester while fetal cells are still specializing. If the pregnancy is confirmed, the parents would be advised about the potential hazards to the baby.

Testosterone use does not appear to pose any risk to a breastfeeding baby, as the components of the drug are largely metabolized before they reach the bloodstream, breast milk, or other body fluids. Similarly, testosterone use in cis men does not pose any risk to a pregnancy, either during conception or gestation.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Endo Pharmaceuticals Solutions Inc. Delatestryl® (Testosterone Enanthate Injection, USP) [packaging label]. Updated October 2016.

  2. Corona G, Torres LO, Maggi M. Testosterone therapy: What we have learned from trials. J Sex Med. 2020;17(3):447-460. doi:10.1016/j.jsxm.2019.11.270

  3. Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016;5(6):877-884. doi:10.21037/tau.2016.09.04

  4. Giri, D.; Patil, P.; Blair, J. et al. Testosterone therapy improves the first year height velocity in adolescent boys with constitutional delay of growth and pubertyInt J Endocrinol Metab. 2017;15(2): e42311. doi:10.5812/ijem.42311

  5. Boni C, Pagano M, Panebianco M, et al. Therapeutic activity of testosterone in metastatic breast cancerAnticancer Res. 2014;34(3):1287-90.

  6. Pfizer. DEPO-TESTOSTERONE. Indications and Usage.

  7. U.S. Food & Drug Administration. FDA approves new changes to testosterone labeling regarding the risks associated with abuse and dependence of testosterone and other anabolic androgenic steroids (AAS). Published October 25, 2016.

  8. Michigan Medicine, University of Michigan. Testosterone injection. Updated May 13, 2019.

  9. Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015;17(2):212-6. doi:10.4103/1008-682X.140966

  10. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7(6):378-87. doi:10.1177/1756287215597633

  11. Morgentaler, A.; Lipshultz, L.; Bennett, R. et al. Testosterone therapy in men with untreated prostate cancerJ Urol. 2011;185(4):1256-60. doi:10.1016/j.juro.2010.11.084

  12. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-5. doi:10.1007/s10549-005-9074-y

  13. Petering RC, Brooks NA. Testosterone therapy: Review of clinical applications. Am Fam Physician. 2017;96(7):441-449.